Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H17N |
Molecular Weight | 175.2701 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1(CCCCC1)C2=CC=CC=C2
InChI
InChIKey=RGZGRPPQZUQUCR-UHFFFAOYSA-N
InChI=1S/C12H17N/c13-12(9-5-2-6-10-12)11-7-3-1-4-8-11/h1,3-4,7-8H,2,5-6,9-10,13H2
Molecular Formula | C12H17N |
Molecular Weight | 175.2701 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: NMDA receptor-coupled channels Sources: https://www.ncbi.nlm.nih.gov/pubmed/2659775 |
PubMed
Title | Date | PubMed |
---|---|---|
The ability of new non-competitive glutamate receptor blockers to weaken motor disorders in animals. | 2003 Mar |
|
[Effects of blockade of ionotropic glutamate receptors on the development of pentylenetetrazole kindling in mice]. | 2005 Nov |
|
Effects of ionotropic glutamate receptor channel blockers on the development of pentylenetetrazol kindling in mice. | 2007 Jan |
Substance Class |
Chemical
Created
by
admin
on
Edited
Sun Dec 18 02:13:54 UTC 2022
by
admin
on
Sun Dec 18 02:13:54 UTC 2022
|
Record UNII |
HBO2D49I2S
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DEA NO. |
7460
Created by
admin on Sun Dec 18 02:13:54 UTC 2022 , Edited by admin on Sun Dec 18 02:13:54 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID30176449
Created by
admin on Sun Dec 18 02:13:54 UTC 2022 , Edited by admin on Sun Dec 18 02:13:54 UTC 2022
|
PRIMARY | |||
|
31862
Created by
admin on Sun Dec 18 02:13:54 UTC 2022 , Edited by admin on Sun Dec 18 02:13:54 UTC 2022
|
PRIMARY | |||
|
2201-24-3
Created by
admin on Sun Dec 18 02:13:54 UTC 2022 , Edited by admin on Sun Dec 18 02:13:54 UTC 2022
|
PRIMARY | |||
|
HBO2D49I2S
Created by
admin on Sun Dec 18 02:13:54 UTC 2022 , Edited by admin on Sun Dec 18 02:13:54 UTC 2022
|
PRIMARY | |||
|
DB01506
Created by
admin on Sun Dec 18 02:13:54 UTC 2022 , Edited by admin on Sun Dec 18 02:13:54 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE |
This metabolite was detected in rat urine. However, according to this journal acticle, “The authors' experience in metabolism and analytical studies on rats and humans support the assumption that the metabolites found in rat urine should also be present in human urine. Therefore, it can be concluded that the procedure described here should also be applicable for human urine screening for PCEEA and/or PCMEA in clinical or forensic cases. However, their differentiation would only be possible through detection of the respective parent drug or unique metabolites.”
URINE
|
||
|
PARENT -> METABOLITE |
This metabolite was detected in rat urine. However, according to this journal acticle, “The authors' experience in metabolism and analytical studies on rats and humans support the assumption that the metabolites found in rat urine should also be present in human urine. Therefore, it can be concluded that the procedure described here should also be applicable for human urine screening for PCEEA and/or PCMEA in clinical or forensic cases. However, their differentiation would only be possible through detection of the respective parent drug or unique metabolites.”
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |